Hedera Dx: Getting everybody tested for cancer when it matters most.
Location: United States, Indiana, York
Employees: 11-50
Total raised: $30.86M
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | Bootstrap ... | bootstrap-... |
| 18.03.2022 | Air Street... | airstreet.... |
| 11.06.2025 | Tesi | tesi.fi |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.05.2025 | - | $17.01M | - |
| 22.09.2022 | Seed | $13.86M | - |
Mentions in press and media 15
| Date | Title | Description |
| 23.01.2026 | ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials | ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting ... |
| 21.01.2026 | French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers | ErVimmune, a BioTech company out of Lyon developing cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that do not respond to current immunotherapies – today announces the first closing of its €17 million ($19.8 million)... |
| 21.12.2025 | T-CURX Secures $20M Series A to Advance Non-Viral CAR-T Cancer Therapies | German biotech T-CURX closed a $20 million Series A funding round. The Würzburg-based company will accelerate clinical development of its non-viral CAR-T cell therapies. These innovative treatments target acute myeloid leukemia (AML) and so... |
| 17.12.2025 | German startup T-CURX secures €17.7 million to support development of new cancer treatments | Würzburg-based T-CURX today announces the first closing of a €17.7 million Series A to accelerate clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary ... |
| 29.05.2025 | Revolutionizing Cancer Care: Hedera Dx Secures €15 Million to Expand Access Globally | In the world of healthcare, innovation is the lifeblood that keeps the industry moving forward. A recent infusion of €15 million into Hedera Dx, a Lausanne-based biotech company, exemplifies this spirit. This funding, part of a Series A rou... |
| 27.05.2025 | Hedera Dx raises €15M to bring modern cancer care to patients worldwide | Outside the U.S., where centralized testing dominates, healthcare systems require diagnostics to be performed within hospital labs. Founded in 2021, Hedera Dx has developed blood-based cancer testing solutions, known as liquid biopsies, to... |
| 27.05.2025 | Swiss BioTech Hedera Dx has just bagged €15 million to bring modern cancer care to patients across the globe | Lausanne-based Hedera Dx, a BioTech company, today announced the closing of a €15 million Series A financing round to drive advanced cancer care and overcome structural barriers that prevent cancer patients from accessing targeted cancer th... |
| 16.09.2024 | Positive clinical progress in the biotech scene | With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 10.07.2024 | Hedera Dx setzt neue Massstäbe in der Onkologie-Präzisionsmedizin | Bis anhin setzte man sowohl bei der Krebs-Diagnose als auch bei der weiteren Behandlung und Kontrolle auf Gewebeproben. Diese Art der Biopsie erfordert einen operativen Eingriff und ist deshalb zeitintensiv und nicht ungefährlich. Das Laus... |
| 17.10.2023 | Hedera Dx Launches Blood Based Cancer Testing |
Show more